Logistic regression analyses (Table 4) indicated that there were no significant associations of CYP2C19 and CYP2D6 metabolizer status with switching versus maintained AD treatment and with discontinued versus maintained AD treatment. Here, CYP2C19 is linked to Alzheimer disease.